By Amy Batista, Special Writer
EAST WINDSOR — Mayor Janice Mironov announced that Aurobindo Pharma USA has purchased 90 acres on Windsor Center Drive and plans to develop the site for a major pharmaceutical manufacturing and distribution center, according to a township press release.
“We are excited that Aurobindo has chosen East Windsor for its new warehouse and distribution center, bringing new tax dollars and new jobs to our community,” said Mayor Mironov said. “This expansion here by Aurobindo, a global corporation, represents the attraction to East Windsor of another high-tech, high growth-potential company in our Einstein’s Alley corridor.”
She said that East Windsor is a great location for this type of company, and they are pleased to add Aurobindo to the many pharmaceutical related firms which have chosen to locate in East Windsor, including Novotec Pharma, Hovione, Elementis, CoreTech Solutions, Aprecia, Aurex Laboratories, Sabinsa, and Windsor Labs.”
The project is to expand Aurobindo’s New Jersey footprint and is complementary to the company’s existing facilities, according to the press release.
The purchased property is located across from Route 133 and near the 43,000 square foot Patscentre building, now occupied by Novo Tech, a new Township pharmaceutical R&D company. The new facility is expected to generate at least 300 new jobs at the East Windsor location when fully operational, according to the press release.
“This new acquisition and proposed facility highlights the Township’s strong business appeal and the tremendous benefits of this commercial site which, with the turnpike improvements, now also enjoys direct access to East Windsor Turnpike Interchange 8,” Mayor Mironov said.
Aurobindo Pharma USA is a generic pharmaceutical manufacturer and distributor and is a wholly-owned subsidiary of Aurobindo Pharma Limited, a leading generic pharmaceutical company based in India. The company’s portfolio includes a wide array of products covering many therapeutic areas and disease states for both the retail and institutional markets, according to the press release.
“We at Aurobindo Pharma are very excited about our recent acquisition and planned expansion into East Windsor,” said Aurobindo USA’s Chief Executive Officer Robert Cunard in a press release. “We have appreciated the valuable assistance and guidance of the Mayor and her team, who have been great partners and extremely helpful to our company in moving forward with our acquisition and planned expansion.”
He said they look forward to a long and successful collaboration, and becoming a member of the East Windsor business community.
“East Windsor is a perfect location for Aurobindo’s goal of an expanded U.S. and New Jersey presence,” he said.
Headquartered in Hyderabad, India, Aurobindo’s main US manufacturing center is located in Dayton. The East Windsor location will be the company’s main distribution center and also will provide another site for manufacturing. Founded in 1986, and becoming a public company in 1992, and has business operations in more than 125 countries around the world, according to the press release.
